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Summary 
The microtubule binding affinities of a series of synthetic taxanes have been 
measured with the aims of dissecting individual group contributions and obtaining a 
rationale for the design of novel compounds with the ability to overcome drug 
resistance. As previously observed for epothilones, the positive and negative 
contributions of the different substituents to the binding free energies are cumulative. 
By combining the most favourable substitutions we increased the binding affinity of 
paclitaxel 500-fold. Insight into the structural basis for this improvement was gained 
with molecular modelling and NMR data obtained for microtubule-bound docetaxel. 
Taxanes with affinities for microtubules well above their affinities for P-glycoprotein 
are shown not to be affected by multidrug resistance. This finding strongly indicates 
that optimization of the ligand-target interaction is a good strategy to overcome 
multidrug resistance mediated by efflux pumps. 
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Introduction 
Cancer is one of the major causes of premature death in humans and 
multidrug resistance (MDR) of neoplastic tissues is a major obstacle in cancer 
chemotherapy. While many tumours initially respond favourably to chemotherapeutic 
treatment, effectiveness at tumour regression is limited by the development of 
resistance. Although several primary reasons account for the MDR, the predominant 
cause is the overexpression and drug efflux activity of several transmembrane 
proteins, as best exemplified by P-glycoprotein (P-gp) (Shabbits et al. 2001).  
P-gp is a member of the ATP binding cassette (ABC) family, with broad 
substrate specificity for substances including anticancer drugs, peptides, and HIV 
protease inhibitors. It has been shown that the extent of drug resistance in human 
tumours correlates well with P-gp expression (Tan et al. 2000). 
In a previous work with a small group of C-2 substituted cephalomannines 
(CPHs) (Yang et al. 2007) we noticed that the resistance indexes for high-affinity 
taxanes in MDR cells are much lower than those for the medium-affinity taxanes, 
paclitaxel (TXL) and docetaxel (DXL), used in clinical practice. These results 
suggested that increasing the binding affinity of these compounds might be an 
alternative to overcome MDR, the rationale for this being that affinity for tubulin is the 
main force driving the entrance of the ligand into cells. 
When MDR cells are exposed to taxanes, two opposite forces control ligand 
uptake: on the one hand, binding to P-gp, which will pump the ligand out of the cell, 
and on the other hand, binding to tubulin, which will reduce the intracellular 
concentration of the ligand and will keep it bound inside the cell. Thus, the higher the 
binding affinity of the ligand for tubulin, the lower the intracellular concentration of free 
ligand. Since efflux relies on drug binding to P-gp, which in turn depends on free 
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ligand concentration, at intracellular ligand concentrations far below its dissociation 
constant from P-gp, the efflux will be strongly decreased. In the most extreme case of 
a ligand that binds covalently to the taxane site, such as the natural product 
cyclostreptin, every molecule entering the cell will be finally trapped by tubulin and the 
tumour cell’s MDR phenotype will be completely circumvented (Buey et al. 2007). 
Although numerous chemical and biological qualitative studies of the structure-
activity relationships of taxanes have been performed ((Zefirova et al. 2005), 
(Kingston et al. 2007), an in-depth study of the contributions of the different 
substituents to the binding thermodynamics has not been performed. We have 
previously shown that for epothilone (EPO) derivatives (Buey et al. 2004) the 
thermodynamic contributions of the substituents are accumulative, that is, the same 
substitution on different ligands produces a similar change on the binding affinity. The 
effect of a single modification can thus be quantified, and both favourable and 
unfavourable contributions can be combined to build tailor-made ligands with the 
desired affinities. 
We now report on the thermodynamics of binding of a set of 44 taxanes (called 
Chitax (CTX)), plus the three reference compounds, TXL, DXL and CPH (Figure 1), to 
cross-linked stabilized microtubules (MT) in order to quantify the contributions of 
single modifications at four specific locations of the taxane scaffold: two of them, C2, 
in the southern part of the molecule, and C13, where side chains have been 
described as essential for taxane activity (Chen et al. 1993b), and another two, C7 
and C10, in the northern part of the molecule, where substituents have been shown 
as non-essential for taxane activity (Chen et al. 1993a)). It is known that the side 
chains at these positions accept modifications that modulate the activity, both 
favourably and unfavourably (Ojima et al. 1997), (Kingston et al. 1998), (Yang et al. 
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2007). The activity of these taxanes was investigated against the parental (A2780) 
and MDR P-gp–overexpressing (A2780AD) human ovarian carcinoma cell lines 
(Rogan et al. 1984). We were able to correlate the binding affinity of these tubulin 
ligands to their cytotoxicity in the resistant cells. Moreover, the resulting 
thermodynamic data was used to design novel high-affinity taxanes with the ability to 
overcome P-gp–related resistance. The higher affinity of these newly designed 
compounds has been rationalized by experimentally determining the tubulin bound 
conformation of DXL and by modelling the complexes of DXL, TXL and the best of the 
designed taxanes within the binding site of β-tubulin. 
 
Results 
Thermodynamics of binding of TXL analogues to stabilized MTs. 
 All the compounds were first shown to be TXL-like MT-stabilizing agents (MSA) 
(Supplemental Table I). Then, their affinity for the taxane-binding site was measured 
using the competition method previously employed (Buey et al. 2004) (Table I and 
Supplemental Table II). Every compound was initially measured using Flutax-2 as the 
competitor. Compounds 4, 11, 12, 13, 14, 19, 20 and 21 displayed very high affinities, 
completely displacing Flutax-2 at equimolar concentrations (Figure 2A). This indicated 
that they were in the limit of the range of measurement allowed by the previously 
employed test (Díaz et al. 2007). 
 To measure the binding affinity of these compounds more precisely, we used a 
direct competition experiment with a higher-affinity compound, EPO-B, whose binding 
affinity (7.5x108 M-1 at 35 ºC) has been previously determined (Buey et al. 2005) 
(Figure 2B). This allowed the precise determination of the binding affinities of 
compounds 4, 11, 12, 13, 14, 19, 20 and 21, whose values range between 1.42x108 
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M-1 for the compound with the lowest affinity, CTX-21, and 1.51x109 M-1 for the 
highest-affinity compound, CTX-12. This method was validated when the binding 
affinities of compounds 11, 13, 19 and 21 (those in the range of 108 M-1) were shown 
to be similar using either EPO-B or Flutax-2 (Supplemental Data) .  
To confirm that the high affinity of compounds containing 3-N3 Benzoyl at C2 
does not originates from covalent binding of its reactive azido group to β-tubulin, we 
performed experiments in which the amounts of reversibly bound compounds 4, 12 
and 14 were measured. The bound compounds could be extracted from the pellets 
and aqueous solutions with the aid of an organic solvent, indicating that they are not 
irreversibly bound. 
 
Molecular Modelling 
One conspicuous characteristic of the taxane-binding site in β-tubulin (Lowe et 
al. 2001) is the presence of the highly exposed side chain of His229 (located in the 
middle of helix 7 and positionally equivalent to Arg229 in α-tubulin) that splits the 
cavity into two major pockets. Because continuum electrostatic calculations predicted 
the imidazole ring of this residue to be doubly protonated at pH 6.5 (pKHis229=7.2), this 
ionization state was used in subsequent work.  
 Molecular dynamics (MD) studies of TXL, DXL and CTX-40 in aqueous 
solution provided us with a range of different conformers, the most abundant of which 
(Supplemental Figure S1) were independently studied in a first rigid-body approach 
by the automated docking program. Interestingly, the conformation previously 
reported for TXL (Lowe et al. 2001) (Snyder et al. 2001) using either DOCK or FlexX 
was also found by AutoDock amongst the best scoring solutions. Since similar poses 
were found for DXL (Supplemental Figure S2) and CTX-40 as well, this common 
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disposition of the taxane in the binding site of β-tubulin was used in the modelling of 
all the complexes. Noteworthy, these conformations are not the most populated in 
aqueous solution (data not shown) although they are sporadically observed in the 
course of transitions toward other more stable and “hydrophobically collapsed” 
conformations. The proposed docked conformation for TXL is then in fact coincident 
with that previously found in crystals of 7-mesylpaclitaxel, which was reportedly 
induced by specific interactions of the side chain at C13 with solvent (Gao et al. 
1996). 
The feasibility of the resulting modelled complexes was assessed by subjecting 
each of them to a 10-ns MD simulation followed by a simulated annealing procedure 
that provided us with a set of representative complex structures for further analysis 
and energy decomposition. In all cases, the ligand adopts a conformation in good 
agreement with the T-taxol geometry (Snyder et al. 2001) (Figure 3) and is anchored 
in the binding site through a common set of well-defined interactions. Thus, the 
oxetane oxygen of the taxane is engaged in a good hydrogen bond with the NH of 
Thr276 whereas another hydrogen bond is established between the amide or 
carbamate carbonyl oxygen on the C13 substituent and the Nε of His229. On the 
other hand, the common phenyl ring at C13 (3’-Ph) establishes very close van der 
Waals contacts with the hydrophobic side chains of Val23 and Ala233 whereas the 
benzoyl phenyl ring at C2 (2-OBz) gets lodged into another hydrophobic cavity, on the 
other side of His229, made up of the side chains of Leu217, Leu219, and Leu275. 
The offset stacking interaction of this latter phenyl with the imidazole ring of His229 
(Supplemental Figure S3) is improved by the substituent at the meta position, whose 
1,2- (methoxy, CTX-13) or 1,3-dipole (azide, CTX-40) additionally establishes a 
favourable electrostatic interaction with the amide dipole of the backbone peptide 
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bond between His229 and Leu230 (Figure 3). Of the three hydroxyl groups that are 
common to the four ligands studied, that present on the C13 substituent is 
consistently engaged in a hydrogen bonding interaction with the carboxylate of Asp26 
in helix 1 and the backbone nitrogen of Arg369 whereas that at C7 can establish 
transient hydrogen bonds with the carboxamide group of Gln282. On the other hand, 
the hydroxyl at C1 is permanently exposed to the solvent.  
The four complexes yielded very low RMS deviations for the protein atoms with 
respect to the refined β-tubulin–TXL structure 1JFF (~1.3 Å on average for 400 
atoms). The major differences when compared to this particular complex are the 
presence of a different rotameric state for His229, which we propose is protonated at 
physiological pH, and improved stacking and hydrogen bonding interactions between 
the ligand and the protein as a consequence of the mutual adaptation brought about 
by the simulated annealing procedure. 
 
 NMR characterization of bound docetaxel 
As a further step, and to provide an experimentally-based support for the 
modelling-derived conformations, which formed the basis for the quest of the 
structure-activity relationship, the MT-bound conformation of DXL was elucidated, 
under the experimental conditions used for determining the binding constants 
(supplementary file DXLNMR.pdb). 
As previously shown, the transferred nuclear Overhauser enhancement (TR-
NOESY) technique provides an adequate means to determine the bound 
conformation of ligands that exchange between free and bound states at a reasonably 
fast rate. TR-NOESY experiments were then performed on the DXL:MT sample at 
different mixing times. Negative crosspeaks were clearly observed at 310 K (Figure 4, 
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panels A and B), as expected for a ligand that binds to the assembled MTs 
preparation, in contrast with the lack of NOEs detected in the free state (Figure 4, 
panel C). 
 Two control experiments were performed employing either Flutax-2 instead of 
DXL (the effective koff of Flutax-2 release from MTs is 1.63±0.18 s-1 (Diaz et al. 2000)) 
or both DXL and discodermolide (DDM) at equimolecular concentrations. No TR-
NOESY signals were observed in the presence of Flutax-2, indicating that the 
effective koff of DXL is higher than that previously measured for Flutax-2, and the DXL 
signals were cancelled out by DDM (whose affinity for the TXL-binding site is 100 
times higher), indicating that DXL is effectively bound to the TXL site (Buey et al. 
2005). 
 
 Cytotoxicity in resistant and nonresistant tumour cells. 
To check the effects of the studied modifications on the cytotoxicities of the 
compounds and to validate the binding affinity approach as a tool to be used in ligand 
optimization we performed IC50 tests in A2780 human ovarian carcinoma cells and 
their MDR A2780AD counterparts (Table I, Figure 5A). 
The cytotoxicities of the ligands in non-P-gp-overexpressing A2780 cells show 
a linear relationship (r = 0.81) with their binding affinities but only for those 
compounds with a ΔG at 35 ºC higher than –47.5 kJ mol-1 (Kb at 35 ºC higher than 108 
M-1), which points to a limit in the cytotoxicity that can be achieved. Thus, despite the 
increase in affinity of 3 orders of magnitude between CPH and CTX-40, the IC50 
remained in the order of nanomolar. 
In the case of the MDR A2780AD cells, a good linear relationship (r = 0.80) 
between cytotoxicities and binding affinities is observed for the full set of ligands, 
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strongly suggesting that for these P-gp–overexpressing cells tubulin binding is the 
main force competing with P-gp–mediated extrusion. 
The best regression lines have slopes of 1.10 for A2780 cells and 0.61 for 
A2780AD cells, which indicates that P-gp–overexpression effectively reduces the 
intracellular drug concentration thus making it necessary to increase the load in order 
to exert a cytotoxic effect.  
 
Intake of taxanes by tumour cells  
The amount of compound made available for binding to the tubulin site was 
measured by employing radioactively labelled DXL and TXL, at the concentrations 
needed to stop the cell cycle in G2/M, in two leukemic cell lines (U937 and K562) and 
the kidney epithelial non-tumour cell line PtK2 from Potorus tridactylis. In these 
conditions, the intracellular drug concentration, which ranges from 0.3 to 2.8 μM and 
represents a small percentage of the total drug and the cell tubulin concentrations 
(Supplemental Table III), increases with the total drug concentration and reaches a 
maximum in PtK2 cells at 300 nM DXL and 600 nM TXL. The equilibration of the 
ligand inside the cells is fast, with a half-life of 3 minutes for 14C-DXL and 10 minutes 
for 3H-TXL at a drug concentration of 1 μM. The drug inside the cell was found to be 
in the cytoplasm, with only a very small fraction bound to the nucleus, as expected.  
Since the total intracellular drug concentration is more than one order of 
magnitude above its MT dissociation constant and much lower than the total tubulin 
concentration (which was considered to be ~5% of the total protein measured), the 
mass action law dictates that most of the compound inside the cells is essentially 
bound to tubulin and also that the intracellular concentration of free drug is close to 
the dissociation constant, i.e. 70 nM for TXL and 25 nM for DXL. 
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Discussion 
The effects of modifications on the substituents attached to the baccatin 
scaffold on the cytotoxicity of taxanes have been qualitatively discussed in several 
reviews (Zefirova et al. 2005), (Kingston et al. 2007). However, the fact that these 
studies were performed in different cell lines precludes a rigorous evaluation of the 
relationship between structural changes and cytotoxicity. To quantify the effects of 
substitutions at a set of specific positions in a systematic way, the binding affinity for 
the taxane-binding site on β-tubulin has proved to be a more precise and objective 
parameter (Buey et al. 2004). 
 With all the binding constants determined at a given temperature (35 ºC), it has 
been possible to determine the changes in apparent binding free energy caused by 
single group modifications (Table II) and to select the most favourable substituents at 
the positions chosen for optimization. Once this knowledge was obtained, it became 
feasible to design several optimized taxanes, as demonstrated below. 
 
(1) Effect on the binding affinity of changes at the C2 position. 
C2 modifications have turned out to be the most effective in modulating the 
activity of taxanes. Thus, the 2-OBz is absolutely essential since either its removal 
(Chen et al. 1993b) or its replacement with other small side chains (Ojima et al. 
1994), (Nicolaou et al. 1995) results in almost total loss of activity in the human colon 
cancer cell line tested. On the contrary, changes in the structure of the ring, including 
its replacement with non-aromatic or heterocyclic rings, result in only moderate losses 
of antitumour activity (Ojima et al. 1994). Introduction of substituents on the 2-OBz 
ring, (Nicolaou et al. 1994), (Kingston et al. 1998), (Yang et al. 2007) results in 
increases of activity for small groups at the meta position but loss of activity for the 
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other positions. Changes in the linker connecting the benzene ring to the taxane core 
also result in decreased biological activity (Wang et al. 2007). 
 Our results confirm and extend the qualitative data summarized above and 
provide a precise quantitative characterization of the effects of C2 modifications on 
binding affinity:  
a) Changing the nature of the linker between the benzene ring and the taxane 
scaffold results in a large loss of binding free energy. Thus, the replacement of the 
ester by an ether, thioether or amine moiety (compounds 24, 25, 26, 27, 38 and 39) or 
by a thioester or an amide (compounds 22, 23, 42, 43 and 44) results in a heavy loss 
of binding free energy (up to 20 kJ mol-1). This stringent requirement indicates that the  
angle between the benzyl ring and the taxane core has to be strictly preserved and 
must be related to steric hindrance, as previously discussed for the thiobenzoyl 
compounds 22 and 23 (Wang et al. 2007), because the analogues in which the benzyl 
group is replaced by an alkyl ester (compounds 2, 3, 9, 10 and 16) only display a 
moderate loss of binding free energy (5–6 kJ mol-1), which can be assigned to the 
loss of interactions between the benzyl ring and the binding site. 
 b) Modification of the meta substituents on the benzyl ring leads to gains of 
binding free energy that are the largest for –N3 (–11.2±1.1 kJ mol-1) and –OCH3 (–7.2 
kJ mol-1) substituents (compounds 4, 5, 11, 12, 13, 14, 20) and much smaller (–2-3 kJ 
mol-1) for halogen atoms (compounds 6, 30 and 34) whereas other small groups (–CN 
and –CH3) have no effect (compounds 7 and 8). On the other hand, other similarly 
small substitutions (–OH and –CH2OH), (compounds 36 and 37), are detrimental, 
resulting in a loss of 7–9 kJ mol-1 of binding free energy. 
 c) Introduction of double substituents at the 2,4 (compounds 28, 29) and 2,5 
(35) positions results in loss of binding affinity.  
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d) The thienoyl moiety (compounds 31 and 32) can effectively replace the 
benzoyl group. 
 Because previous work from our group (Buey et al. 2004), has shown that 
substitutions leading to gains in binding free energy also give rise to increased 
cytotoxicity, the –N3 substituent at the meta position of 2-OBz was selected as the 
most suitable for molecule optimization.  
 
(2) Effect on the binding affinity of changes at the C13 position. 
The side chains present at position C13 in one semisynthetic (DXL) and two 
natural taxanes (CPH and TXL) were evaluated in order to choose the optimal one for 
binding. Although from the direct comparison of TXL and DXL alone (Diaz et al. 1993) 
it is not possible to assess the effect of the C13 side chain on the binding free energy 
due to the presence of additional differences in the substituents at C7 and C10, DXL 
showed a 1.9–fold larger binding affinity relative to TXL, which corresponds to a 
change of –1.6 kJ mol-1 in free energy of binding. A similar difference (2x) was 
observed in the cytotoxicity on 1A9 cells (Buey et al. 2005). On the other hand, the 
tubulin binding affinity and the cytotoxicity of CPH are about two times lower than 
those of DXL (Yang et al. 2007). 
In our series, by comparing compounds TXL, DXL, CPH, 11, 12, 13, 14, 15, 17, 
20, 21, 22, 23, 24, 25, 26, 27, 38, 39 and 40 differing only in the side chain at C13 
present in the reference molecules, we can now establish that, of the three side 
chains, that of DXL provides the largest contribution to the binding free energy,  (ΔΔG 
C13-DXL−C13-TXL=–3.2±0.9 kJ mol-1, ΔΔG C13-CPH−C13-DXL= –5.6±1.1 kJ mol-1). 
(3) Effect on the binding affinity of the substituents present in the northern side of the 
taxane ring (C7 and C10). 
 14
Modifications on the northern face of TXL at positions C7 and C10 have little 
effect on tubulin binding, as expected from the previously described effects on 
cytotoxicity (Chen et al. 1993a). From all the substituents tested at C10, the best one 
turns out to be the propionyl group, which provides an incremental free energy 
change of around –0.5 kJmol-1 over the natural C10 acetyl. On the contrary, 
introduction of the same group at position C7 brings about a loss of 1.6 kJ mol-1 of 
binding free energy relative to the –OH present in TXL. For this reason, a propionyl at 
C10 and a hydroxyl at C7 were selected as optimal substituents at these positions. 
 
Optimal taxane 
According to the data measured, “the optimal taxane” should have DXL’s side 
chain at C13, an m-N3-benzoyl at C2, a propionyl at C10, and a hydroxyl at C7. 
Starting from compound 1, the first one in the series, with an apparent binding affinity 
of –39.4 kJ mol-1, the resulting molecule should gain –5.6 kJ mol-1 from the 
replacement of the CPH side chain with that of DXL, –11.2 kJ mol-1 from the 
substitution of m-N3-benzoyl for benzoyl at C2, –1.6 kJ mol-1 from the change of a 
propionyl at C7 to a hydroxyl, and –0.9 kJ mol-1 from the change of a hydroxyl at C10 
to a propionyl. Taking all of these changes together, the optimal taxane would have a 
predicted ΔG at 35 ºC of –58.7 kJ mol-1. When the compound was synthesized (CTX-
40) and its binding affinity was measured using the EPO-B displacement method (Kb 
35ºC=6.28±0.15x109 M-1; ΔG = –57.7±0.1 kJ mol-1), the experimental value was found 
to be in nice correspondence with the predicted value. 
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Structural interpretation of the binding data  
Two different reasons have been proposed for the changes in activity due to 
modifications at C2, i) the need for a hydrophobic group to maintain the proper taxane 
conformation, or ii) direct interactions of the benzoyl with hydrophobic side chains of 
the protein (Zefirova et al. 2005). The modelling data support the view that the higher 
affinity of CTX-40 relative to TXL and DXL, which is mostly conferred by the 
phenylazide substituent present at C2, may largely stem from the simultaneous 
improvement of the stacking interactions with the imidazole ring of His229(+) and a 
better electrostatic interaction with Asp26 and Arg369 on the opposite side of the 
molecule resulting from a better anchoring of the ligand in the binding site. The same 
rationale applies to CTX-13, which has a methoxy substituent in place of the 
azide, and to a lesser extent for the derivatives containing halogen atoms. As regards 
the methyl, cyano, hydroxyl or hydroxymethyl substituents, they are likely to be found 
facing the solvent rather than orientated towards the binding pocket thus contributing 
negligibly to the binding affinity, in good accord with the experimental evidence. 
  Likewise, the enhanced affinity contribution of the DXL and CTX-40 side-
chain at C13 relative to that of TXL arises from an improved hydrogen-bonding 
interaction of the carbamate NH relative to the amide NH with the carboxylate of 
Asp26. 
 
Pre-release conformation of bound docetaxel. 
Transferred NOESY signals arise from a free DXL molecule whose protons 
have been excited when still bound to the protein but have been relaxed after release 
from the binding site. Thus, the conformation deduced from these signals 
corresponds to a pre-release state of the ligand. It has been described that MT-
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stabilizing agents binding to the TXL site reach their luminal final location through 
prior transient binding to a site located in the MT pore (Diaz et al. 2003), (Buey et al. 
2007). Therefore the NMR structural data have to be interpreted with this caution.  
Since DXT release from MT following excitation has to be fast in order to get 
trNOESY signals, the Koff of the ligand should be fast in the relaxation time scale. This 
is apparently in contradiction with the slow dissociation constant measured for TXL in 
a kinetic study, 0.091±0.006 s-1 (Diaz et al. 2003). Nonetheless this observed 
dissociation constant does not correspond to the release step but to the rate-limiting 
step of the reaction. The dissociation of taxanes from MT has been studied in detail 
using the fluorescent taxane derivatives Flutax-1 and Flutax-2, which dissociate from 
MT following a two-step mechanism (Diaz et al. 2000). The first step, which is the 
slower one (thus the one directly observed), has a kinetic rate constant of 
0.022±0.001 s-1 (4-fold slower than that of TXL) while the second one (responsible for 
the release of the ligand to the medium and which can be measured only indirectly 
from the dependence of the kinetic rate constants on concentration) is nearly 100 
times faster (koff=1.63±0.18 s-1). 
In the absence of the fluorescent probe it is not possible to calculate the value 
of the kinetic rate constant of the release step of DXL dissociation (koff). Control  
experiments with Flutax-2 performed in the same conditions did not show any 
trNOESY signal from this ligand, which indicates that its koff value is not large enough 
to provide good trNOESY signals. Therefore, the effective kinetic rate of the release 
step of the dissociation process of DXL has to be higher. Since it is not unreasonable 
to think that the presence of the fluorescein moiety slows down the dissociation of 
Flutax-2 and the observed trNOESY crosspeaks for the DXL:MT ensemble are 
cancelled out by addition of DDM (a TXL-binding site ligand with a much higher 
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affinity (Buey et al. 2005)), it can be assumed that the detected signals arise from 
DXL in the last step of dissociation from MT which may be bound to either the 
external site or to a modified luminal site. 
The basic features of the NMR-derived conformation might be extracted from 
the trNOESY crosspeaks. Clear NOEs are observed between the t-butyl protons and 
the 2-OBz protons (Figure 4B), while only extremely weak NOEs are observed 
between both aromatic (2-OBz and 3’-Ph) moieties (Figure 4D). The OAc-4 group 
also provides NOEs with both aromatic rings (Figure 4B). These experimental 
observations allow us to discard the presence of the so-called polar conformation for 
DXL when this molecule is bound to MT. The NMR-derived conformation is thus 
basically in agreement with the conformation derived from the modelling approach 
(see Supplemental Figure S4). Nevertheless, whilst the modelled structure is in 
agreement with the so-called T-taxol geometry (Snyder et al. 2001), the NMR-derived 
conformation is intermediate between this one and that dubbed collapsed-geometry 
(Vandervelde et al. 1993). In any case, the fact that both conformations are fairly 
similar and indeed resemble the T-taxol conformation possibly indicates that the 
prerelease step does not largely affect the conformation of DXL, and that the T-taxol 
conformation is stable in the protein environment. The only observed difference is 
probably due to the presence of His229, which in the modelled structure is found 
between the 2-OBz and the C13 side chain, thus further separating these two 
moieties. The NMR observations are in agreement with a closer proximity between 
the OBz and the tBu protons (ca. 4-5 Å) than that suggested by the modelled DXL–β-
tubulin complex (ca. 5-6 Å). Under these constraints, the NMR-deduced prerelease 
bound geometry for DXL, which is close to that of T-taxol, is in agreement with that 
derived by the modelling procedure, and resembles that described for the tubulin-
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bound conformation of TXL (Lowe et al. 2001) although the experimental conditions 
herein are markedly different. 
 
Binding affinity, cytotoxicity and P-gp-overexpression-mediated multidrug resistance. 
 The double log plots representing cytotoxicity vs. tubulin binding affinity (Figure 
5A) clearly indicate that, as in the case of EPOs and other taxane-binding site ligands, 
both magnitudes are related, with the binding affinity behaving as a good predictor of 
cytotoxicity. However, a deviation of the predicted behaviour can be noted from this 
data. There is an apparent cytotoxicity limit (IC50 = 1 nM) for these compounds 
against the non–P-gp–overexpressing cells. A review of the results from our earlier 
work (Buey et al. 2004), (Buey et al. 2005) indicates that there are no MSA with an 
IC50 below nM in these cells. Despite having binding constants of the order of 109 M-1, 
DDM and several EPOs have IC50´s in the order of 1 nM or higher. In fact, cis-CP-tmt-
EPO-B (compound 19 in (Buey et al. 2004)), the compound with the highest affinity 
for the TXL-binding site so far described (2.1x1010 M-1) and also the most cytotoxic 
(IC50 = 0.1 nM), displays a binding affinity three orders of magnitude above that of 
TXL but only a 10-fold increase in cytotoxicity (Buey et al. 2004). These data suggest 
that a significant percentage of tubulin within the cell has to be bound to stop the cell 
cycle and thereby cytotoxicity is limited by the amount of compound that is needed to 
achieve this goal. 
 At the drug concentrations required to stop cell-cycle progression, the 
percentage of tubulin bound by the ligand is in the range of 2–20% of the whole 
available protein. In the drug intake experiments, the total amount of compound 
available at the concentrations needed to stop the cell cycle (or at the IC50) is around 
one third (comparable) of the total amount of tubulin. Although this should be enough, 
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in principle, for binding to a significant percentage of the protein, the results indicate 
that the amount of ligand available for binding to the sites is effectively much smaller 
(2–10 %). The reason for this might be that while all the binding sites are inside the 
small volume occupied by the cells, the drugs have to pass through the cell 
membranes and reach a threshold intracellular concentration that is opposed by the 
detoxification pumps. If a significant percentage (say 2–5%) of cytoplasmic tubulin 
has to be bound for the taxane to exert its cytotoxicity and the amount of ligand 
available for protein binding is a small percentage (2-10%) of the total 1 nM 
concentrations, which is already a third of the total amount of tubulin in the cells, it 
comes out that for the MSA with a taxane way of action the 0.1–1 nM concentration is 
a limit for its cytotoxicity in cells. The same reasoning can be applied to a systemically 
distributed drug for which the minimal amount needed to kill the tumour cells is related 
to the amount of tubulin available for binding, which imposes a practical limit on the 
lowest dose that can be used. 
However, if the goal is not to find a drug with the highest cytotoxicity possible 
(in fact, none of the newly synthesized high-affinity compounds has a remarkably 
better cytotoxicity on nonresistant cells than have TXL and DXL) but rather to find one 
with the ability to overcome the main problem appearing in patients undergoing 
treatment with MSA, namely P-gp–mediated resistance, attempts to increase the 
affinity would seem to be steps in the right direction. Cells overexpressing P-gp are in 
fact still sensitive to taxanes because they can still be killed by higher concentrations 
of either TXL or DXL. Nonetheless, since these concentrations are very high, normal 
non-tumour cells will also be affected and even differentially killed because of their 
inability to reduce the intracellular drug concentration instead of being differentially 
spared because of their lower division rate.  
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The data with A2780AD cells shows the expected correlation (although with a 
lower slope arising from their ability to reduce the intracellular drug concentration) 
between affinity and cytotoxicity that was previously observed for chemically related 
compounds (Buey et al. 2004) with no deviations being noted at the highest 
cytotoxicity values (9 nM for CTX-40). In this type of MDR cells the high-affinity drugs 
are nearly 100-fold more cytotoxic than the clinically employed taxanes (TXL and 
DXL) and display very low resistance indexes (as low as 1.3 for the highest affinity 
derivative, CTX-40). This result was confirmed with LoVo human colon carcinoma 
cells and their MDR LoVo-Dox counterparts (Grandi et al. 1986) (see Supplemental 
Data).  
When the resistance indexes of the compounds are represented against their 
binding affinities (Figure 5B), a bell-shaped curve is observed: the resistance index 
shows a maximum for taxanes displaying similar affinities for tubulin and P-gp, and 
then rapidly decreases when the affinity of the compound for tubulin either increases 
or decreases. An exception to this rule is found for compounds having a halogen 
atom (or a methoxy group) at the meta position of 2-OBz (CTX-5, 6, 30, 34 and 35) as 
they exhibit a much lower resistance index than that of other compounds with 
equivalent affinity.  
The results confirm our previous data with other high-affinity ligands or with 
covalent binders (which can be considered to have infinite affinity) whose cytotoxicity 
is unaffected by P-gp overexpression (e.g. DDM: IC50 values of 60 nM and 53 nM (I. 
Barasoain, unpublished data), or cyclostreptin: IC50 values of 43.5 nM and 51 nM 
(Buey et al. 2007) against A2780 and A2780AD cells, respectively), which is a clear 
indication that ligands with high affinity for the taxane-binding site can overcome the 
P-gp–mediated MDR phenotype. The rationale for this finding is that, in these cells, 
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the intracellular free concentration of the high-affinity binding drugs will be very low 
(see Supplemental Data (Figures S5, S6 and S7) for a detailed mathematical model). 
It is obvious that for the ligand to be pumped out it first has to bind to P-gp, and 
assuming that the kinetics of drug efflux follows a Michaelis-Menten behaviour, the 
ligand outflow will decrease with lower free ligand concentration. Since these ligands 
are tightly bound to tubulin, their intracellular free concentrations are of the order of 
their dissociation constants, which in the case of the high-affinity compounds (Kd of 
CTX-40 = 0.16 nM at 35ºC) are far below their dissociation constants from P-gp 
(which range between 35 nM for TXL and 88 nM for CTX-7) (Yang et al. 2007). This 
implies that, at concentrations able to exert cytotoxicity, the efficacy of P-gp to pump 
out the high-affinity compounds will be reduced by a factor between 200 and 1000 
(see Supplemental Data). From the chemical point of view, this means that P-gp 
overexpression is irrelevant.  
On the other hand, the low-affinity tubulin-binding ligands may escape the 
effect of the pump through a different mechanism. Since they need to reach 
concentrations that are much higher than those of either tubulin or P-gp to bind their 
target and thereby exert their cytotoxicity, the pump gets overloaded (saturated) and 
cannot effectively reduce the intracellular drug concentration. For this reason these 
ligands act as MDR reversal agents by themselves (Brooks et al. 2003). 
The present results support the view (Buey et al. 2005, Buey et al. 2004) that 
binding affinity is the main variable to be maximized in attempts to increase the 
cytotoxicity of this type of compounds (although on nonresistant cells a practical limit 
is observed at around 1 nM concentration). Additionally, the high-affinity compounds 
can escape MDR due to P-gp overexpression by lowering the concentration of free 
ligand that can be pumped out by P-gp.  
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Significance. 
The binding affinities of a series of synthetic taxanes for MTs have been 
measured with the aims of dissecting individual group contributions and obtaining a 
rationale for the design of novel compounds with the ability to overcome drug 
resistance. As previously observed for EPOs, the positive and negative contributions 
of the different substituents to the binding free energy are cumulative. By combining 
the most favourable substitutions in one single analogue the binding affinity was 
increased 500-fold over that of TXL. Insight into the structural basis for this 
improvement was gained when models were built that assigned an important role to 
the interactions of C2 and C13 substituents with the protonated side chain of His229. 
The relative orientation of these groups was found to be in agreement with NMR data 
obtained for MT-bound DXL. 
The cytotoxicities of the compounds in ovarian carcinoma A2780 cells were 
found to correlate with their affinities, with an apparent cytotoxicity limit in the 
nanomolar range. A bell-shaped curve was obtained when the taxane resistance 
index was plotted versus the binding affinity showing that the P-gp–overexpressing 
multidrug resistant A2780AD cells are sensitive to the highest and lowest affinity 
compounds, whereas resistance indexes in the range of 100 to 1000 were obtained 
for those whose binding affinities for tubulin and P-gp are similar.  
The finding that taxanes with affinities for MTs well above their affinities for P-
gp are not affected by multidrug resistance strongly indicates that for a series of 
compounds with similar pharmacokinetic and bioavailability properties, optimization of 
the ligand-target interaction is a good strategy to overcome multidrug resistance 
mediated by efflux pumps. 
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Experimental procedures. 
Proteins and ligands.  
Purified calf brain tubulin and chemicals were as described (Diaz et al. 1993). 
Full details of the synthesis and characterization of the ligands employed can be 
found as Supplemental Data.  
 
Ligand-induced tubulin assembly. 
Critical concentrations of ligand-induced tubulin assembly were measured as 
described (Buey et al. 2005).  
 
Equilibrium binding constants of the ligands to MTs and tubulin.  
The binding constants of the ligands with apparent binding affinities below 108 
M-1 for the TXL-binding site were measured as described (Buey et al. 2004). For the 
EPO-B method, samples of 1 mL containing 1 μM sites in glutaraldehyde-stabilized 
MTs, 1.1 μM EPO-B and 1.1 μM of the test compound in GAB (glycerol assembly 
buffer; 3.4 M glycerol, 10 mM sodium phosphate, 6 mM MgCl2, and 1 mM EGTA, pH 
6.7) with 0.1 mM GTP were incubated for 30 minutes at 35 ºC in polycarbonate 
centrifuge tubes (Beckman). The samples were then centrifuged at 90,000 x g for 20 
minutes at 35 ºC in a TLA-100.2 rotor employing a Beckman Optima TLX 
ultracentrifuge. The supernatants were collected by pipetting, and the pellets were 
resuspended in 10 mM phosphate buffer pH 7.0. 1 μM TXL was added as the internal 
standard, except for the experiments with CTX-13 in which 1 μM DXL was used 
instead. Both the pellets and the supernatants were extracted three times with an 
excess volume of dichloromethane, dried in vacuum and dissolved in 35 μl of 
methanol. The samples were analyzed by HPLC as described below 
 24
Reversibility of binding was checked by incubating samples containing 5 μM 
compounds 4, 12 or 14 and 10 μM taxoid binding sites in stabilized crosslinked MT, 
for 30 min at 25ºC in polycarbonate centrifuge tubes (Beckman) in GAB with 0.1 mM 
GTP (DMSO concentration was always kept under 2%). The samples were then 
centrifuged at 90000 g for 10 min at 25ºC in a Beckman Optima TLX ultracentrifuge 
with a TLA100 rotor, processed and analyzed as described above. 
Binding constants for compounds reversibly displacing Flutax-2 or EPO-B were 
calculated using Equigra v5 (Díaz et al. 2007). The thermodynamic parameters 
(apparent ΔG0, ΔH0 and ΔS0) were calculated as described (Buey et al. 2005).  
Binding of the compounds to unassembled dimeric tubulin was measured by 
centrifugation. 200 μL samples containing 20 μM tubulin and 25 μM compound in 10 
mM phosphate 1 mM EDTA, pH 7.0 buffer (PEDTA) containing 1 mM GDP were 
incubated for 1 h at 35 ºC in polycarbonate centrifuge tubes (Beckman). The samples 
were then centrifuged at 386,000 x g for 1 h at 35 ºC in a TLA100 rotor employing a 
Beckman Optima TLX ultracentrifuge. The upper and lower 100 μL of the solution 
were carefully collected by pipetting, and the pellets were resuspended in 10 mM 
phosphate buffer pH 7.0. The tubulin concentrations in the three samples were 
measured by the Bradford assay, and 5 μM DXL was added as the internal standard. 
The samples were extracted and analyzed as described above. 
HPLC analysis of all samples was performed in an Agilent 1100 series 
instrument employing a Supercosil, LC18 DB, 250x4.6 mm, 5 mm bead diameter 
column developed in a gradient from 50–80% (v/v) acetonitrile in water at a flow rate 
of 1 mL min-1, following the absorbance at λ=220 nm. 
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Cell biology studies. 
PtK2 (kidney epitelial cell from Potorus tridactylis), U937 (monocytic human 
leukemia), K562 (myelocytic human leukemia), A2780, P-gp–overexpressing 
A2780AD (ovarian carcinoma) cells were cultured as previously described (Buey et al. 
2005). Cytotoxicity assays were performed with the MTT assay  modified as 
described in (Yang et al. 2007). 
Cell intake of 3H-TXL and 14C-DXL were measured as reported (Manfredi et al. 
1982) with modifications, using PtK2, U937, K562  cells. These cells, and especially 
the PtK2 cells, were used because they are more resistant to taxanes and more 
reproducible results could be obtained. Cells were grown in 24-well plates at a density 
of 500,000 cells/mL (PtK2) or 300,000 cells/mL (leukemic cell lines) and were 
incubated in 1 mL of medium with the desired drug concentration.  Supernatants were 
collected and cells were washed 3 times with 1 mL of cold PBS and incubated 
overnight with 0.25 mL of NaOH 0.1M, and then neutralized with 0.25 mL of HCl 0.1 
M. The total protein concentration was determined by the Lowry method and the drug 
(both in the supernatants and incorporated into cells) was measured by liquid 
scintillation counting in a LKB 1219 spectrometer. The correction for unspecific 
binding was determined by measuring the amount incorporated in cells preincubated 
with 10 μM colchicine for 4 h at 37ºC and washed three times prior to the incubation 
with 3H-TXL or 14C-DXL. Cell volume was calculated from the volume occupied by the 
pellets and was found to be 2.5±0.2, 3.96±0.05 and 4.3±0.9 μL/106 cells for U937, 
K562 and PtK2, respectively.  
The amounts of drugs bound to the nucleus and cytoplasm of the cells were 
determined as described in (Simpson et al. 1987). 
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Molecular Modelling 
The refined structure of the α,β-tubulin dimer at 3.5 Å resolution (Lowe et al. 
2001) (Protein Data Bank code 1JFF) was used for molecular modelling and ligand 
docking. Addition of missing hydrogen atoms and computation of the protonation state 
of ionizable groups in β-tubulin at pH 6.5 were carried out using the H++ Web server 
(Gordon et al. 2005), which relies on AMBER (Cornell et al. 1995) force-field 
parameters and finite difference solutions to the Poisson–Boltzmann equation. The 
molecular graphics program PyMOL (DeLano Scientific LLC) was employed for 
molecular visualization and representation. The charge distribution for the ligands 
studied was obtained by fitting the quantum mechanically calculated (RHF 6-31G*\\3-
21G*) molecular electrostatic potential (MEP) to a point charge model, as 
implemented in Gaussian 03 (Gaussian, Inc., Wallingford CT, USA). Consistent 
bonded and nonbonded AMBER parameters were assigned to ligand atoms in the 
taxanes by analogy or through interpolation from those already present in the AMBER 
database (ff03).  
The Lamarckian genetic algorithm implemented in AutoDock 3.0.5 (Morris et al. 
1998) was used to generate automated docked poses of TXL, DXL, CTX-13, and 
CTX-40 within the taxane-binding site by randomly changing the overall orientation of 
conformers from the MD ensembles that were representative of the major 
populations, as well as the torsion angle involving the 2-OBz.  
 
NMR experiments 
The NMR experiments were performed at 310 K in D2O as described 
(Jimenez-Barbero et al. 2006) with modifications described in supplementary data, on 
a Bruker AVANCE 500 spectrometer.  
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Figure Legends 
Figure 1. Chemical structure of the taxanes employed in this study. 
Figure 2. (A) Displacement of the fluorescent taxane Flutax-2 bound to MT sites (50 
nM) by taxanes at 35 ºC. The solid lines were generated with the best fit value of the 
binding equilibrium constant of the competitors with binding affinities lower to 107 M-1, 
assuming a one-to-one binding to the same site. Additional lines (dashed lines) show 
the expected displacement for ligands with binding constants of 108 M-1 (black), 109 
M-1 (red), 1010 M-1 (green), and 1011 M-1 (yellow). Ligands binding data are as follows: 
green CPH, red CTX-2, yellow CTX-6, dark blue, CTX-11, magenta CTX-12, light blue 
CTX-14, black CTX-27. (B) Displacement of EPO-B bound to MT sites (10 μM) by 
CTX-40 at 35 ºC. 1 μM TXL-binding sites were incubated with 1.1 μM EPO-B (black 
lines) or with 1.1 μM EPO-B and 1.1 μM CTX-40 (red lines), MTs were harvested by 
sedimentation, ligands extracted from supernatants (solid lines) and pellets (dashed 
lines) and HPLC analyzed. 1 μM TXL is used as the internal standard. Supernatant 
traces were displaced 40 mAU for presentation purposes. 
Figure 3.-TXL (A) and CTX-40 (B) in the binding site of β-tubulin at the end of the 
simulated annealing procedure. Note that the doubly protonated imidazole ring of 
His229 participates in (i) a hydrogen bonding interaction with the amide or carbamate 
carbonyl oxygen on the C13 substituent through the Nε, and (ii) an offset stacking 
interaction with the phenyl ring on the C2 substituent. 
Figure 4. A.- The 500 MHz TR-NOESY (mixing 200 ms, 303 K) spectrum of DXL in 
buffered water solution in the presence of MTs (20:1 molar ratio). B.-  Expansion 
showing the key TR-NOESY region: close contacts between the tert-butyl chain and 
the aromatic 2-OBz ring (besides the trivial cross peaks with the vicinal 3’-Ph moiety). 
C.- The NOESY experiment under the same experimental conditions (200 ms) in the 
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absence of MTs did not basically show any cross peak. D.- Expansion of the aromatic 
region in the TR-NOESY spectrum: Basically, no NOEs between the two aromatic 3’-
Ph and 2-OBz moieties are observed. 
Figure 5. (A) Dependence of the IC50 of the ligands against A2780 (black) and 
A2780AD (grey) human ovarian carcinoma cells on the affinity for the TXL-binding 
site in MTs (binding constant, Kb). The black line represents the best fit of IC50 against 
A2780 cells vs binding affinity for ligands with binding affinity under 5x108 M-1. The 
grey line represents the best fit of IC50 against A2780AD cells vs binding affinity. (B) 
Dependence of the resistance index of the A2780AD MDR cells on the affinity of the 
compounds for the taxane binding site. The range of binding affinities of taxanes for 
P-gp was taken from (Yang et al. 2007). 
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Tables. 
Table I. Apparent binding affinities, thermodynamic parameters of binding of taxanes for the TXL site (107 M-1) and cytotoxicity of 
the compounds to non-resistant and resistant ovarian carcinoma cells. 
Compound Kb 35ºC ΔG 35ºC kJ/mol  ΔH kJ/mol ΔS J/mol IC50 A2780 nM IC50 A2780AD nM R/S 
TXLa 1.43±0.17 -42.1±0.3 -51±4 -29±13 1.3±0.4 980±149 753 
DXLa 3.93±0.27 -44.8±0.2 -53±2 -26±8 0.6±0.2 290±16 483 
CPH 0.69±0.08 -40.3±0.3 -39±6 -6±18 1.5±0.2 910±285 606 
CTX-1 0.49±0.12 -39.4±0.6 -56±12 -56±39 13.2±7 1222±300 92.5 
CTX-2 0.043±0.018 -33.2±0.9 -66±18 -109±38 950±80 10200±1900 10.7 
CTX-3 0.072±0.017 -34.5±0.5 -32±9 10±29 1250±200 4000±700 3.2 
CTX 4b 87±19 -52.7±0.5 -46±13 19±44 2.7 ±0.6 14±3.8 5.2 
CTX-5 5.37±1.39 -45.6±0.6 -40±4 19±14 6.6±1.8 160±19 24.2 
CTX-6 1.62±0.24 -42.5±0.4 -39±2 13±7 10±2.4 274±30 27.4 
CTX-7 0.39±0.06 -38.8±0.4 -38±5 4±17 14.5±2.9 2100±660 145 
CTX-8 0.492±0.073 -39.4±0.3 -28±3 39±10 22.5±5 596±105 26.4 
CTX-9 0.028±0.008 -32.1±0.6 -15±4 56±12 3900±370 15000±3500 3.8 
CTX-10 0.042±0.008 -33.1±0.4 -12±5 68±18 4900±600 >20000 >4 
CTX 11b 38±10 -50.5±0.6 -14±20 117±65 1.36±0.2 163±37 120 
CTX 12b 151±3 -54.1±0.1 -29±9 84±29 2.8±0.38 42±13 15 
CTX 13b 16.5±2.8 -48.4±0.4 -28±1 66±1 1.3±0.2 128±17 98.4 
CTX 14b 80.0±2.9 -52.5±0.1 -46±6 21±19 1.6±0.3 25±10 15.6 
CTX-15 2.384±0.53 -43.5±0.5 -18±11 80±35 17.5±2.7 5250±1000 300 
CTX-16 0.050±0.030 -33.6±1.2 -18±9 49±30 740±100 7360±750 9.9 
CTX-17 0.902±0.37 -41.0±0.9 -24±3 55±10 18±5.6 5412±1200 301 
CTX-18 1.281±0.27 -41.9±0.5 -22±4 64±14 2.1±0.8 452±36 215.2 
CTX 19b 14.8±0.2 -48.2±0.1 -48±3 0±9 0.54±0.07 39±11 72.2 
CTX 20b 80.6±5.1 -52.5±0.2 -92±19 -124±64 3.9±1.2 27.4±4 7 
CTX 21b 14.2±1.6 -48.0±0.3 -26±5 72±16 1.9±0.3 41±11 21.5 
CTX-22 0.013±0.00 -30.1±0.0 -46±7 -151±23 2400±1000 6960±670 2.9 
CTX-23 0.007±0.00 -28.6±0.0 -37±7 -123±22 11500±1000 23800±2200 2.1 
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CTX-24 0.094±0.01 -35.2±0.3 -65±10 -95±33 353±19 8600±3800 24.3 
CTX-25 0.008±0.00 -28.9±0.0 -47±7 -154±24 6200±2600 28500±5300 4.6 
CTX-26 0.018±0.00 -31.0±0.0 -73±11 -77±137 3500±1400 8300±2700 2.4 
CTX-27 0.007±0.00 -28.6±0.0 -42±6 -138±21 10000±740 9400±1700 0.94 
CTX-28 0.17±0.04 -36.7±0.5 -17±8 62±25 82±16 1880±200 22.9 
CTX-29 0.25±0.08 -37.7±0.7 -52±9 -48±30 102±8.8 690±60 6.8 
CTX-30 1.76±0.91 -42.7±1.1 -11±15 92±49 30±0.5 246±27 8.2 
CTX-31 0.10±0.04 -35.4±0.9 -44±11 -30±36 106±4.2 2950±480 27.8 
CTX-32 0.24±0.08 -37.6±0.7 -7±16 87±55 62±17 3200±250 51.6 
CTX-33 0.07±0.01 -34.4±0.3 -81±12 -152±39 69±77 1500±100 21.7 
CTX-34 1.20±0.93 -41.7±1.5 -38±28 14±94 28.7±1.9 196±14 6.8 
CTX 35 0.88±0.77 -40.9±1.6 -29±33 13±112 25±2 153±39 6.12 
CTX 36 0.029±0.020 -32.2±1.3 -48±6 -63±18 1700±120 >20000 >11.7 
CTX 37 0.035±0.010 -32.7±0.6 -91±7 -207±24 86±9.8 10000±1000 116.2 
CTX 38 0.001±0.001 -23.6±1.8 -44±9 -70±34 15400±3200 20000±3000 1.3 
CTX 39 0.003±0.001 -26.4±0.7 -157±10 -461±28 4200±100 5700±300 1.3 
CTX 40b 628±15 -57.7±0.1 -26±24 99±80 7±1 9.1±0.45 1.3 
CTX 41 0.021±0.004 -31.4±0.4 -94±9 -202±28 14000±2000 >20000 1.4 
CTX 42 0.008±0.003 -28.9±0.8 -106±13 -250±43 192±20 2750±430 14.3 
CTX 43 0.030±0.008 -32.3±0.6 -85±20 -169±66 69.5±3.8 331±70 4.8 
CTX 44 0.001±0.001 -23.6±1.8 -177±23 -493±75 >20000 >20000  
 
a) Binding affinity and thermodynamic parameters data are from (Buey et al. 2004). 
b) Compounds measured with the EPO-B displacing method 
Errors bars are standard errors of the mean 
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Table II. Incremental free energy of binding of TXL analogues to MTs due to single 
group modifications. 
 
Modification 
type. 
Modification Compounds ΔΔG Avg  
(Std Err) 
C2 Benzoyl → benzylether T→25 +13.2 +13.0±0.2 
  21→24 +12.8  
 Benzoyl → benzylsulphur T→27 +13.6 +15.9±2.3 
  21→26 +18.1  
 Benzoyl → benzylamine T→38 +18.6 +20.1±1.5 
  21→39 +21.6  
 Benzoyl → thiobenzoyl T→23 +19.6 +15.9±3.8 
  21→22 +12.1  
 Benzoyl → benzamide 21→42 +19.2  
 Benzamide → 3-OCH3-benzamide 42→43 -3.4  
 Benzamide → 3-Cl-benzamide 42→44 +5.3  
 Benzoyl → 3-methyl- 2 butenoyl 1→2 +6.2  
 Benzoyl → 3-methyl- 3 butenoyl 1→3 +4.9  
 Benzoyl → 2(E)-butenoyl 1→9 +7.3  
 Benzoyl → 3-methyl- butanoyl 1→10 +6.3  
 Benzoyl → 2-debenzoyl-1,2-carbonate C→16 +5.8  
 Benzoyl → 3-N3 Benzoyl 1→4 -8.0 -11.2±1.3 
  T→12 -13.9  
  C→14 -12.2  
  18→20 -10.6  
 Benzoyl → 3-OCH3-benzoyl 1→5 -6.2 -7.2±0.6 
  T→11 -8.3  
  C→13 -8.1  
  18→19 -6.3  
 Benzoyl → 3-Cl-benzoyl 1→6 -3.1  
 Benzoyl → 3-Br-benzoyl 1→34 -2.3  
 Benzoyl → 3-I-benzoyl 1→30 -3.3  
 Benzoyl → 3-NC-benzoyl 1→7 +0.6  
 Benzoyl → 3-CH3-benzoyl 1→8 0.0  
 Benzoyl → 3-CH2OH-benzoyl 1→36 +7.2  
 Benzoyl → 3-OH-benzoyl 18→37 +9.2  
 3-Cl-Benzoyl → 2,4-di-Cl-benzoyl 6→29 +4.8  
 Benzoyl → 2,4-di-F-benzoyl 1→28 +2.7  
 3-OCH3-Benzoyl → 2-5-di- OCH3-
benzoyl  
5→35 +4.6  
 Benzoyl → 2-thienoyl 1→31 +4.1  
 Benzoyl → 3-thienoyl 1→32 +1.8  
 Benzoyl → 6-carboxy-pyran-2-one 1→41 +8.1  
C13  Side Chain TXL → CPH T→C +1.9 +2.0±0.2 
  11→13 +1.9  
  12→14 +1.6  
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  15→17 +2.4  
 TXL → DXL 23→22 -1.7 -3.2±0.9 
  25→24 -6.2  
  27→26 -1.3  
  38→39 -2.8  
  T→21 -4.2  
 CPH → DXL C→21 -3.8 -5.6±1.1 
  17→D -7.7  
  20→40 -5.2  
C10 Acetyl  → –OH T→15 -1.3 -1.7±0.8 
  C→17 -0.7  
  21→D -3.2  
 Propionyl → –OH 18→17 +0.9 +0.9 
 Acetyl → propionyl C→18 -1.6 -0.5±0.4 
  13→19 +0.2  
  14→20 0.0  
C7 Propionyl → –OH 17→1 -1.6 -1.6 
 
Errors bars are standard errors of the mean 
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